Compare KTTA & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTTA | RGNT |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Israel |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 20.4M |
| IPO Year | N/A | N/A |
| Metric | KTTA | RGNT |
|---|---|---|
| Price | $0.80 | $2.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 307.9K | 6.4K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $2.01 |
| 52 Week High | $2.06 | $8.35 |
| Indicator | KTTA | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 24.88 |
| Support Level | $0.67 | N/A |
| Resistance Level | $0.87 | $3.35 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 45.64 | 14.53 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.